Blackstone Life Sciences, the biopharma investing arm of private equity firm Blackstone Group, has made its first strike. It has joined with Novartis (NYSE: NVS) to start a new biotech, Anthos Therapeutics, backed with $250 million in cash and rights to an experimental drug originally discovered by the Swiss firm.
The Cambridge, MA, startup, Anthos Therapeutics, will use the investment to advance MAA868, a Novartis antibody drug that is meant to treat blood clots by targeting two clotting proteins, Factor XI and Factor XIa. Anthos believes the drug has the ability to “prevent a variety of cardiovascular disorders,” like atrial… Read more »
